Comparing AI and human interpretation for lung cancer screening

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of an AI diagnostic system compared to human radiologists in interpreting CT scans for lung cancer screening in community health centers. The study involves randomized controlled methods where expert radiologists set reference standards, and an independent committee assesses cases from both AI-assisted and manual interpretations. Key metrics include diagnostic accuracy, operational efficiency, and cost-effectiveness, with discrepancies resolved by blinded analysts to ensure reliable results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 45-74 years
2. Permanent resident of participating study communities
3. No prior history of lung cancer and no lung cancer screening within the past 3 months
4. Able to comprehend and voluntarily sign informed consent, with willingness to participate in long-term follow-up

Exclusion Criteria:

1. Individuals with a confirmed diagnosis of lung cancer
2. Those with severe comorbidities contraindicating CT imaging
3. Inability to understand study protocols or provide informed consent due to cognitive impairment
4. Concurrent participation in other clinical trials that may interfere with study outcomes
5. Unable to comply with follow-up requirements

Where it's running

• the First Affiliated Hospital of Guangzhou Medical University,
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Jianxing He
• Email: drjianxing.he@gmail.com
• Phone: +8618320729913

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Postpartum exercise to improve heart and metabolic health in women at high risk for preeclampsia

  This pilot study tests whether a 12‑week postpartum exercise program can improve heart health and metabolic markers in women who were at high risk for preeclampsia.

  Recruiting Chinese University of Hong Kong · Hong Kong, Hong Kong · NCT07921173

• AI-assisted whole-course management for safe medicine use in advanced solid tumors

  A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.

  Recruiting at 2 sites Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT07917351

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

• Suzetrigine for pain relief after knee replacement

  This trial tests whether suzetrigine can reduce opioid use after a total knee replacement compared with placebo.

  Recruiting Phase 3 Hospital for Special Surgery, New York · New York, New York · NCT07864896

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.